about
Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell TherapyMAIT cells are activated during human viral infectionsAnalysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing propertiesClinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current PerspectivesAltered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease.Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseasesThe role of chemokines in the recruitment of lymphocytes to the liver.Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.Monocyte subsets in human liver disease show distinct phenotypic and functional characteristicsOptions for treatment of primary biliary cirrhosis.Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cellsOsteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in miceOsteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1.Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients.HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression.Regulatory T-cell directed therapies in liver diseases.Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales.Autoimmune hepatitis: an approach to disease understanding and management.Recruitment mechanisms of primary and malignant B cells to the human liver.Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance.Persistent pyrexia post-liver transplantation: a unique case of pericardial tuberculosis.Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease.Flares during long-term entecavir therapy in chronic hepatitis B.CD161(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-γHuman intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosisEntecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis scoreCorrigendum to "Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy".Supporting evidence for natural killer T cell accumulation in progressive nonalcoholic fatty liver disease?Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?Mycophenolate mofetil as second line therapy in autoimmune hepatitis?Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation.Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score.The regulation of T-cell recruitment to the human liver during acute liver failure.
P50
Q26742101-9BCA0CB5-B65B-42B9-9225-1AE18F1F16CDQ27469032-7522EE2D-DEDB-4C6E-B5D9-6BCF70A74942Q27491282-DA71AF36-EC5F-4AA5-ABC8-318A7FC3F850Q28069832-9570251E-6A38-4C8D-9098-775073C45691Q33522868-6FDD0927-C630-430C-8919-0F2DDF325D38Q33650813-F9B632C5-5C78-410E-9CF3-8B0D9C0407FEQ33906565-5056A7BD-0F24-4E9F-B695-45B9FBE47562Q33977201-1FBFF938-88FC-4710-BA54-C32FA1451227Q34060210-6CE1FCDA-FD4B-4E72-9340-3BAC652B55F8Q34326022-ADFB4833-4C82-401D-9348-CE137A1FDEFAQ34354186-6B46FACA-6252-4A19-83D7-C94D84E809A1Q34511187-A1EC7AFE-6760-4FED-A065-006B55EAE94CQ35669203-B230D075-3284-40D3-AAF1-5DE1C906116AQ35805769-CE0645CA-0194-4FEA-ABF7-2B33E0D563ADQ36588292-7963082E-FB61-4D45-BC10-8F1D5ACD3813Q36770339-59469B53-3D6E-4F09-AA6C-A1BB6AB1B04DQ36828161-2ADC9C19-F022-466A-9E50-8443D6379DA2Q37080623-71EE7E75-CF0D-4D27-88CC-C5212A3FF283Q37363966-2B333644-93A8-4908-99F8-A7D9E5FB8933Q38111152-23DEBDF2-AB7B-4968-AB6D-598AEE0F948FQ38471669-BF90A28B-15D6-4C13-9C10-3BFDBD9CF6ACQ38494826-D9F0B4BD-BD5A-4042-8B05-7D82A428D16DQ39363836-E97C254A-734A-4A97-B37C-095781D1509DQ39866377-0977260A-7AD4-4BF9-B725-9396E69D5406Q40402510-86CB8F2C-974F-4C34-9A66-06818C578277Q40403494-B1B9C8D6-F2B3-4045-A46B-AD51EF2C1FC1Q40441464-6168F8FA-D67C-4109-9F6B-02B604992A4EQ40579422-116CAE8C-9E27-435A-8DAA-F49546D325FEQ40743395-09AB4500-296D-4845-82D0-B9A4CA15BD26Q41550051-A019B470-495A-4C36-9418-28670AE16A2EQ42108248-AB55B879-A339-47D7-AA2C-812A52ECF88EQ42206668-11748C08-9C14-4A08-9D5F-39EE7C2AAEEDQ42247631-D93C0D4A-E580-4816-946A-FE91590D87C1Q42359099-3B29F657-6DE6-4B71-8486-5E204B35E116Q43208275-383D1BFD-E82F-43D6-9FCB-6014A7CB6A94Q45341848-84234ECA-7267-419F-B74F-009CB0307EA1Q46317682-C2962D44-745C-4ECB-8F29-AA43F92284B2Q46831252-1211A49C-E707-4FC2-8FE2-47991718980EQ47099669-3D2AD8C1-654B-43C2-8719-B8D4DBF63FFAQ51042074-A690ABF5-9958-478C-8308-824571F00F8F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ye H Oo
@ast
Ye H Oo
@en
Ye H Oo
@es
Ye H Oo
@nl
Ye H Oo
@sl
type
label
Ye H Oo
@ast
Ye H Oo
@en
Ye H Oo
@es
Ye H Oo
@nl
Ye H Oo
@sl
altLabel
Ye Oo
@en
prefLabel
Ye H Oo
@ast
Ye H Oo
@en
Ye H Oo
@es
Ye H Oo
@nl
Ye H Oo
@sl
P106
P2798
P31
P496
0000-0002-0495-6734